Category: Federal Forum Posters
Purpose: Hepatitis C virus (HCV) infection is a viral disease characterized by liver inflammation which over time can progress to liver cirrhosis and other serious complications. Direct acting antivirals (DAAs) are the treatment of choice with once daily regimens usually taken for three months (12 weeks). However, in certain treatment naive patients, 8 weeks of ledipasvir/sofosbuvir or glecaprevir/pibrentasvir can be used, and these regimens are preferred when indicated. The objective of this project is to evaluate the achievement of sustained virological response (SVR) for 8 weeks of therapy with either ledipasvir/sofosbuvir or glecaprevir/pibrentasvir in our veteran population.
Methods: A retrospective chart review of treatment naïve patients with hepatitis C infection who received glecaprevir/pibrentasvir or ledipasvir/sofosbuvir for a planned 8 weeks of therapy in the past four years (January 2015-September 2018) will be conducted. Treatment outcomes will be retrospectively evaluated for each patient through medical record review at baseline visit, 2 weeks of therapy, 4 weeks of therapy, 8 weeks of therapy (final HCV viral load) and at least 12 weeks post-therapy for SVR attainment (non-detectable HCV viral load ≥ 12 weeks after the end of treatment). Treatment failure will be defined as a detectable viral load at least 12 weeks after treatment.
Additional baseline data to be collected includes: age, race, sex, HCV genotype, presence of cirrhosis (FIB-4 score), relevant co-infections (i.e., HIV and hepatitis B), and renal function. A total of 250 to 300 patients is expected. All patients that completed therapy will be reviewed.
Data will be evaluated with descriptive statistics.
Results: not applicable
Conclusion: not applicable
Lisa Lemoine– Pharmacy Student, University of Louisiana Monroe School of Pharmacy, Bossier City, LA